Entities / Company
Karyopharm Therapeutics (United States).
company in Newton, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 24
What's happening
Gone quiet
No new reports in 90+ days-
Karyopharm Therapeutics shares lost 61.1% on August 12, 2025, compared to the S&P 500's gains.Some support2 reports
-
Karyopharm Therapeutics reported results from its operations in Newton, Massachusetts.Some support2 reports
-
Karyopharm Therapeutics reported successful product launches and regulatory approvals in Europe and China, including market presence in the UK.Some support5 reports1 development inside
-
Karyopharm Therapeutics reported XPOVIO revenue increase and detailed Phase 3 SENTRY trial results for myelofibrosis.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Karyopharm Therapeutics (United States) this week
News at the entities that move Karyopharm Therapeutics (United States) most-
Europe StructuralOmron Healthcare opened its first Indian factory in Chennai to supply Europe and reduce reliance on its Vietnam operations.Moves Karyopharm Therapeutics (United States)
-
China Shared contextSan Miguel's group won the concession bid for NGCP over a Chinese group, highlighting China's interest in the Philippine energy sector.Moves Karyopharm Therapeutics (United States)
-
Newton Shared contextA city councilor in Newton is representing the neighborhood's interests.Moves Karyopharm Therapeutics (United States)
Connections
The 3 strongest of 24, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Europe Structural
Karyopharm Therapeutics requires regulatory approvals from Europe to market its products in the territory.
-
China Shared context
Karyopharm Therapeutics received regulatory approvals, allowing it to operate within the Chinese market.
-
Newton Shared context
Karyopharm Therapeutics is located in Newton, Massachusetts.
History
Events by the month they beganJune 2026
4 events- Karyopharm Therapeutics shares lost 61.1% on August 12, 2025, compared to the S&P 500's gains.
- Karyopharm Therapeutics reported results from its operations in Newton, Massachusetts.
- Karyopharm Therapeutics reported successful product launches and regulatory approvals in Europe and China, including market presence in the UK.
- Karyopharm Therapeutics reported XPOVIO revenue increase and detailed Phase 3 SENTRY trial results for myelofibrosis.